Antidiabetic Activity of Benzopyrone Analogues in Nicotinamide-Streptozotocin Induced Type 2 Diabetes in Rats

Table 1

Percentage reduction of glycemia by treatment with test compounds in nicotinamide-STZ diabetic rats.

Groups	Fasting blood glucose (FBG)		% Reduction of glycemia; (taken from the mean values)
	Day 7	Day 22
G1	90.2 ± 5.30	93.20 ± 9.40	−3.33
G2	188.3 ± 4.4	198.3 ± 12.3^a,b	−5.31
G3	195.3 ± 6.6	108.3 ± 9.80^a,b,c	44.55
G4	196.4 ± 3.5	114.2 ± 11.7^a,b,c	41.86
G5	200.1 ± 8.7	145.2 ± 13.2^a,b,c	27.44
G6	198.4 ± 3.7	132.6 ± 14.8^a,b,c	31.15
G7	198.6 ± 3.8	168.8 ± 10.8^a,b,c	15.01
G8	200.5 ± 2.9	173.2 ± 11.8^a,b,c	13.62

All values are mean ± SEM; (min); G1: normal control; G2: diabetic control (nicotinamide + STZ); G3: diabetic + glibenclamide (2.5 mg/kg); G4: diabetic + quercetin (10 mg/kg); G5: diabetic + JY-1; G6: diabetic + JY-2; G7: diabetic + JY-3; and G8: diabetic + JY-4; (test compounds at optimised dose of 80 mg/kg); ^a < 0.05 FBG on day 22 is compared to FBG on day 7; ^b < 0.05 compared to normal rats (G1); and ^c < 0.05 is compared to diabetic rats (G2) (one-way ANOVA followed by Tukey’s post-hoc test).